Skip to Content

'
Samuel C. Mok

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

   My laboratory has a primary research focus on the studying the role of tumor microenvironment in the pathogenesis of epithelial ovarian cancer. We are particularly interested in evaluating the mechanisms thorough which stromal cell and ovarian cancer interact in the omental tumor microenvironment. My laboratory’s ongoing research projects include the use of next generation RNAseq to characterize non-coding RNAs and mRNAs delivered by cancer associated adipocyte (CAA), cancer associated fibroblast (CAF) and ovarian cancer cell derived exosomes and microvesicles; the use of transcriptome profiling, microdissection techniques, and systems biology approach to identify pathway networks that are activated in different cell types within the ovarian cancer microenvironment; the developing of 3D real-time co-culture models to evaluate the effect of various stromal cells on ovarian cancer cell growth, and invasion and motility potential, and the effect of ovarian cancer cells on angiogenesis; and the study of  the impact of physical properties such as the rigidity of the extracellular matrix on ovarian cancer cell motility and invasion potential.

My Laboratory is also interested in identifying prognostic or predictive markers for ovarian cancer through comparative genomic hybridization (CGH) and transcriptome array analyses. We are particularly interested in functionally characterizing candidates that may be used as therapeutic targets in ovarian cancer treatment. 

Research Interests

  1. Identification of differentially expressed genes in human epithelial ovarian cancer
  2. Genetic alterations in human borderline ovarian tumor
  3. Genetic alterations in papillary seous carcinoma of the peritoneum
  4. Role of signal transduction molecules in ovarian carcinogenesis
  5. Molecular classification of epithelial ovarian tumors
  6. Identification of markers for early detection of ovarian cancer
  7. Stromal and epithelial cell interaction in ovarian cancer pathogenesis
  8. Genetic polymorphisms and ovarian cancer risk
  9. Application of nantotechnology in ovarian cancer detection and treatment

Education & Training

Degree-Granting Education

1987 The Chinese University of Hong Kong, Hong Kong, Hong Kong, PHD, Anatomy
1984 The Chinese University of Hong Kong, Hong Kong, Hong Kong, BS, Biology

Postgraduate Training

1990-1992 Research Fellowship, Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
1989-1990 Research Fellowship, Department of Immunology, Toronto Western Hospital, Toronto, Canada
1987-1989 Postdoctoral Fellow, Dept of Clinical Biochemistry, University of Toronto, Toronto, Ontario, Canada

Selected Publications

Peer-Reviewed Original Research Articles

1. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123(10):4435-48, 10/1/2013. e-Pub 9/9/2013. PMCID: PMC3784549.
2. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130(3):565-9, 9/2013. e-Pub 6/22/2013. PMID: 23800698.
3. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73(16):5016-5028, 8/15/2013. e-Pub 7/3/2013. PMCID: PMC3745588.
4. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2/15/2013. e-Pub 1/23/2013. PMCID: PMC3577959.
5. Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA. Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. PLoS One 8(11):e80314, 2013. e-Pub 11/26/2013. PMCID: PMC3841174.
6. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One 8(12):e81859, 2013. e-Pub 12/2/2013. PMCID: PMC3847080.
7. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. PAX2 Expression in Ovarian Cancer. Int J Mol Sci 14(3):6090-105, 2013. e-Pub 3/15/2013. PMCID: PMC3634442.
8. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng AS, Wong RR, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130(5):1036-45, 3/1/2012. e-Pub 6/2/2011. PMID: 21400511.
9. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7(1):e29079, 2012. e-Pub 1/2012. PMCID: PMC3260150.
10. King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13-8, 10/2011. e-Pub 7/2/2011. PMCID: PMC3171566.
11. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. Am J Surg Pathol 35(6):904-12, 6/2011. e-Pub 3/2011. PMCID: PMC3095702.
12. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393-405, 5/2011. PMCID: PMC3084616.
13. Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI. C-Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. Clin Cancer Res 17(5):1065-74, 3/1/2011. e-Pub 12/1/2010. PMCID: PMC3075966.
14. Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4(3):463-70, 3/2011. e-Pub 1/28/2011. PMCID: PMC3048908.
15. Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC. Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res 4(1):6, 2011. e-Pub 3/2011. PMCID: PMC3077316.
16. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. e-Pub 7/6/2011. PMCID: PMC3130734.
17. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. Am J Pathol 177(4):1611-7, 10/2010. e-Pub 8/2010. PMCID: PMC2947258.
18. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 119(1):114-20, 10/2010. e-Pub 7/8/2010. PMCID: PMC3000175.
19. Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroihet LM, Rho JH, Jin L, Seethappan V, Vitonis A, Wang J, Mok SC, Crum C, Cramer DW, Ye B. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 8(1). e-Pub 6/2010. PMCID: PMC2903602.
20. Chan WY, Xia CL, Yew DT, Zhao H, Mok SC. Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex. Neuroembriology and Aging 5, www.karger.com/nba. e-Pub 1/2010.
21. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-32, 12/8/2009. PMCID: PMC3008560.
22. Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med 100(5):357-70, 10/2009. PMID: 19910889.
23. Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 100(9):1748-56, 9/2009. e-Pub 6/2009. PMCID: PMC2788299.
24. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-50, 9/2009. e-Pub 6/2009. PMCID: PMC2736318.
25. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529-41, 6/2009. PMCID: PMC2685442.
26. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124(6):1358-65, 3/15/2009. PMID: 19065659.
27. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia 11(2):126-35, 2/2009. PMCID: PMC2631137.
28. Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112(2):325-30, 2/2009. e-Pub 10/19/2008. PMID: 18937968.
29. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2642-2650, 12/18/2008. PMCID: PMC2710981.
30. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14(23):7667-73, 12/1/2008. PMCID: PMC3000165.
31. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 9/2008. PMCID: PMC2517641.
32. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in intraplacental and postmolar choriocarcinomas. J Reprod Med 53(8):558-64, 8/2008. PMID: 18773618.
33. Nagymanyoki Z, Growdon WB, Sarno J, Callahan MJ, Parast MM, Fulop V, Mok SC, Horowitz N, Berkowitz RS. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 53(8):589-94, 8/2008. PMID: 18773623.
34. Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW, Ye B. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68(14):5839-48, 7/15/2008. PMCID: PMC2586603.
35. Nagymanyoki Z, Butler MO, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. J Reprod Med 53(7):528-34, 7/2008. PMID: 18720929.
36. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther 7(7):1993-2002, 7/2008. PMCID: PMC2649755.
37. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 109(2):234-9, 5/2008. e-Pub 3/10/2008. PMID: 18331757.
38. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14(3):764-71, 2/1/2008. PMID: 18245537.
39. Nagymanyoki Z, Callahan MJ, Parast MM, Berkowitz RS, Mok SC, Fulop V. Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. Gynecol Oncol 108(1):121-5, 1/2008. e-Pub 10/24/2007. PMID: 17928039.
40. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 622:23-33, 2008. PMID: 18546616.
41. Cheung KK, Mok SC, Rezaie P, Chan WY. Dynamic expression of Dab2 in the mouse embryonic central nervous system. BMC Dev Biol 8:76, 2008. PMCID: PMC2527319.
42. Cheung KK, Mok SC, Zhao H, Rezaie P, Chan WY. Inhibition of Dab2 expression with antisense oligodeoxynucleotides in mouse embryo. Neuroembryol Aging:89-99, 2008.
43. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 18(5). e-Pub 11/16/2007. PMID: 18021219.
44. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecol Oncol 107(2). e-Pub 9/18/2007. PMID: 17878059.
45. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106(2):311-7, 8/2007. e-Pub 5/25/2007. PMCID: PMC1995602.
46. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 6/1/2007. PMID: 17538174.
47. Litkouhi B, Kwong J, Lo CM, Smedley JG, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, Berkowitz RS, Mok SC, Garner EI. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9(4):304-14, 4/2007. PMCID: PMC1854850.
48. Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol 38(1):134-9, 1/2007. e-Pub 9/25/2006. PMID: 16996567.
49. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9(1):23-35, 1/2007. PMCID: PMC1803033.
50. Park DC, Yeo SG, Shin EY, Mok SC, Kim DH. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103(3):996-1000, 12/2006. e-Pub 8/4/2006. PMID: 16890274.
51. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17):8404-12, 9/1/2006. PMID: 16951150.
52. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66(16):7983-90, 8/15/2006. PMID: 16912173.
53. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118(10):2433-40, 5/15/2006. PMID: 16380993.
54. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 4/2006. PMCID: PMC1600675.
55. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101(1):71-5, 4/2006. e-Pub 11/10/2005. PMID: 16290000.
56. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12(2):432-41, 1/15/2006. PMID: 16428483.
57. Feinberg BB, Jack RM, Mok SC, Anderson DJ. Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol 54(6):352-7, 12/2005. PMID: 16305660.
58. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602-12, 11/15/2005. PMID: 16288054.
59. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7, 11/1/2005. PMID: 16278384.
60. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-77, 11/2005. e-Pub 8/2/2005. PMID: 16061277.
61. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19 Pt 1):6880-8, 10/1/2005. PMID: 16203778.
62. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170-3, 9/2005. PMID: 16102589.
63. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5(12):3183-92, 8/2005. PMID: 16035113.
64. Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 159(1):53-7, 5/2005. PMID: 15860358.
65. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6):2162-9, 3/15/2005. PMID: 15781627.
66. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 1/2005. PMID: 15589584.
67. Feltmate CM, Mok SC. Whole-genome allelotyping using laser microdissected tissue. Methods Mol Biol 293:69-77, 2005. PMID: 16028411.
68. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 12/2004. PMID: 15571795.
69. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115(4):327-30, 9/2004. PMID: 15290239.
70. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91(4):725-31, 8/16/2004. PMCID: PMC2364785.
71. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211(2):227-34, 8/2004. PMID: 15219946.
72. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10(10):3474-8, 5/15/2004. PMID: 15161704.
73. Zhou X, Li C, Mok SC, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 151(1):82-4, 5/2004. PMID: 15120915.
74. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67(3-4):291-9, 2004. PMID: 15557791.
75. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98(12):2576-82, 12/2003. PMID: 14669276.
76. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9(13):4811-8, 10/15/2003. PMID: 14581352.
77. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-91, 10/2003. PMID: 14581349.
78. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9(8):2904-11, 8/1/2003. PMID: 12912935.
79. Bandera CA, Tsui HW, Mok SC, Tsui FW. Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. Anticancer Res 23(4):3151-7, Jul-Aug, 7/2003. PMID: 12926048.
80. Ho SM, Lau KM, Mok SC, Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 22(27):4243-56, 7/2003. PMID: 12833147.
81. Batorfi J, Fulop V, Kim JH, Genest DR, Doszpod J, Mod SC, Berkowitz RS. Osteopontin is down-regulated in hydatidiform mole. Gynecol Oncol 89:134-139, 2003.
82. Batorfi J, YE B, Mok SC, Cseh I, Berkowitz RS, Fulop V. Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol Oncol 88:424-428, 2003.
83. Schorge JO, Mok SC. Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes. Hum Pathol 30(2):115-6, 2/1999. PMID: 10029436.
84. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34-7, 1/1999. PMID: 9916952.
85. Iyengar TD, Ng S, Lau CC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene 18(1):257-62, 1/1999. PMID: 9926941.
86. Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 92(4 Pt 1):596-600, 10/1998. PMID: 9764635.
87. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 17(4):419-24, 7/1998. PMID: 9696034.
88. Bandera CA, Muto MG, Welch WR, Berkowitz RS, Mok SC. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 16(26):3455-9, 7/1998. PMID: 9692553.
89. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58(11):2328-30, 6/1998. PMID: 9622067.
90. Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Berkowitz RS, Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90(11):841-5, 6/1998. PMID: 9625172.
91. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16(18):2381-7, 5/1998. PMID: 9620555.
92. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 152(5):1247-58, 5/1998. PMCID: PMC1858596.
93. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):101-10, 2/1998. PMID: 9513871.
94. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43(2):119-27, 2/1998. PMID: 9513873.
95. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 16(2):197-202, 1/1998. PMID: 9464537.
96. Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 14(24):2979-84, 6/1997. PMID: 9205105.
97. Tsao SW, Mok SC, Knapp RC, Oike K, et al. Molecular genetic evident of a unifocal origin for human ovarian cancers. Gyn Oncology 48:5-10, 1993.

Invited Articles

1. Mok SC, Wong KK, Lu K, Nagymanyoki Z. Molecular basis of gynecologic diseases. Molecular Pathology. In Press.
2. Wong KK, Mok SC. Molecular genetics of ovarian cancer. Ovarian Cancer. In Press.
3. Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: Models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila) 2(9):773-5, 9/2009. e-Pub 9/8/2009. PMID: 19737981.
4. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 1/2008. PMID: 19072449.
5. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4(1):121-31, 2/2007. PMID: 17288520.
6. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
7. Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers 23(5-6):389-96, 2007. PMID: 18057522.
8. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-76, 2007. PMID: 18057520.
9. Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med 49(6):415-22, 6/2004. PMID: 15283047.
10. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20(2):53-70, 2004. PMID: 15322314.
11. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15(1):51-5, 2/2003. PMID: 12544502.
12. Fulop V, Mod SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. J Reprod Med 47:369-379, 2002.
13. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 25(3):281-304, 6/1998. PMID: 9633841.

Book Chapters

1. Mok SC, Wong KK, Lu KH, Munger K. Molecular Basis of Gynecologic Diseases. In: Molecular Basis of Human Diseases. Elsevier Science Press. In Press.
2. Feltmate C, Mok SC. Whole genome allelotyping on laser-based microdissected tissue. In: Laser Capture Microdissection: methods and protocols. Ed(s) I Graeme, M Curran and Stephanie Curran. The Humana Press Inc: Totowa, New Jersey, 69-77, 2004.
3. Wong KK, Cheng R, Kim JK, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor-specific clones. In: Perspectives In Gene Expression. Ed(s) K Appasani. BioTechniques Press: Natick, Massachusetts, 2003.
4. Mok SC, Schorge JO, Welch WR, Hendrickson MR, Kempson RL. Peritoneal Tumours. In: World Health Organization of Tumours, Pathology & Genetics, Tumours of the Breast and Female Genital Organs. Ed(s) FA Tavassoli, P Devilee. IARC Press, 197-202, 2003.
5. Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by cDNA microarray. In: Microarray and Cancer. Ed(s) J Warrington, CR Todd, D Wong. Eaton Publishing: Natick, Massachusetts, 127-138, 2002.
6. Mok SC, Lu KH, Ng SW, Yiu GK, Welch WR, Bell DA, Berkowitz RS. Molecular pathogenesis of borderline and invasive ovarian tumors. In: Ovarian Cancer 6. Ed(s) I Jacobs, D Luesley, A Berchuck, T Blackett. Isis Medical Media, 97-103, 2000.
7. Mok SC, Lo KW, Tsao SW. Direct PCR cycle-sequencing of mutated allele detected by PCR-SSCP analysis. In: The PCR Technique: DNA Sequencing II. Ed(s) U Gyllensten, J Ellingboe. Eaton Publishing: Natick, Massachusetts, 69-73, 1997.

Grant & Contract Support

Title: Center for BD2PM: Turning Big Data to Precision Medicine
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Mok
Duration: 7/1/2014 - 6/30/2019
 
Title: ISG15 in Ovarian Cancer Progression
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Mok
Duration: 7/1/2014 - 6/30/2019
 
Title: Can exercise and the prevention of cancer recurrence: How much is enough
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 4/1/2014 - 3/31/2018
 
Title: Uterine SPORE Dev: UCHL-1 as a potential therapeutic target in uterine papillary serous carcinoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2014
 
Title: Can exercise prevent ovarian cancer recurrence: mechanism and biomarkers
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 7/1/2013 - 6/30/2018
 
Title: Novel angiogenic factor in ovarian cancer microenvironment
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 6/1/2013 - 5/31/2016
 
Title: Cancer-stroma interactions in ovarian cancer progression
Funding Source: OCRF
Role: Principal Investigator
Duration: 10/1/2012 - 9/30/2015
 
Title: Novel cancer associated fibroblast derived angiogenic factor in ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/30/2017
 
Title: Novel adipokine in ovarian cancer progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/30/2017
 
Title: Role of the omental microenvironment in ovarian cancer invasion and metastasis
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/30/2017
 
Title: In Vivo Lipofection: Does horizontal transfer of miR21 by omental adipocytes contribute to ovarian cancer progression?
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2012 - 8/30/2017
 
Title: Ovarian SPORE Dev: Novel angiogenic factor in ovarian cancer progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2013
 
Title: Uterine SPORE Dev: Omentin in endometrial cancer progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2013
 
Title: Secreted stromal microRNAs in ovarian cancer progression
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 6/1/2012 - 5/31/2014
 
Title: The omental microenvironment in ovarian cancer: Understanding its role in ovarian cancer progression anc chemoresistance
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2012 - 4/30/2017
 
Title: Dissecting tumor stroma interactions in ovarian carcinoma
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 9/1/2011 - 8/30/2016
 
Title: Genomic structure for ovarian cancer patients
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Michael J Birrer
Duration: 10/1/2010 - 11/30/2013
 
Title: Novel angiogenic factor in ovarian cancer microenvironment
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2010 - 10/31/2013
 
Title: CNV and ovarian cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Charles Lee
Duration: 7/1/2009 - 6/30/2014
 
Title: Prognostic markers for ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 3/1/2009 - 12/31/2014
 
Title: A fresh approach to identification and characterization of early changes of disease associated with ovarian cancer
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Gordon Mills
Duration: 2009 - 2010
 
Title: Early events in ovarian cancer pathogenesis
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Anil Sood
Duration: 2009 - 2010
 
Title: Application of nanotechnology in the targeted release of anticancer drugs in ovarian cancer treatment
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Coleen Feltmate
Duration: 2006 - 2008
 
Title: DF/HCC Ovarian Cancer, Early genetic changes in ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2004 - 2008
 
Title: Prognostic markers for ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2003 - 7/30/2009
 
Title: Genes, Hormones and Environment in ovarian cancer model
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Daniel Cramer
Duration: 2003 - 2008
 
Funding Source: Friends of Dana-Farber
Role: Principal Investigator
Duration: 2003 - 2004
 
Title: Maternal obesity, intrauterine gene expession and breast cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Karin Michels
Duration: 2002 - 2005
 
Title: Identification of markers for early detection of ovarian cancer
Funding Source: Adler Foundation, Inc
Role: Principal Investigator
Duration: 2001 - 2005

Last updated: 7/9/2014